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In their a posteriori analysis of data from a previous
randomized, controlled trial, ‘‘Effectiveness and safety of
repeat courses of hylan G-F 20 in patients with knee
osteoarthritis’’ (2005;13:111e119) by Raynauld et al.1, the
authors concluded that the data indicate no difference in the
safety proﬁle of hylan G-F 20 in patients receiving a single-
vs repeat-course of 3 weekly injections. While I agree that
the use of the hyaluronan class for the chronic pain
management of osteoarthritis (OA) has a favorable safety
proﬁle2, there is a signiﬁcant safety concern related
speciﬁcally to the repeat use of hylan G-F 20. Raynauld
et al. have failed to consider their safety ﬁndings in the
context of the now extensive data regarding the risks of
repeat treatment with hylan G-F 20.
These safety issues have been recently reviewed by
Goldberg and Coutts3 who clinically deﬁned the pseudo-
septic reactions (also termed Severe Acute Inﬂammatory
Reactions, SAIRs) that were encountered with repeat
treatment with hylan G-F 20, outlined appropriate treat-
ments, and reviewed 16 published reports (case reports,
retrospective analyses and clinical studies) documenting
this adverse reaction4. The authors also did not mention the
presumably related and more serious clinical adverse
reaction of severe granulomatous reaction5, which has
now been associated with hylan G-F 20 use in four separate
published reports. While Raynauld et al. did not provide
sufﬁcient details of their adverse event assessments to allow
differential diagnosis, they provided data on the frequency of
arthrocentesis, a primary intervention for SAIRs. They noted
that the rate of arthrocentesis was 0% in the single-course
group and 8.3% in the second-course group (Fisher’s Exact,
PZ 0.007). This result is at odds with their overall
conclusion of no difference in the frequency of adverse
events with repeat- vs single-treatment course.
A statistical comparison was also made between groups
receiving a single course of hylan G-F 20, one repeat
course of hylan G-F 20, and more than one repeat course,
with regard to the incidence of local adverse events and of
the numbers of patients requiring arthrocentesis. This
analysis was conducted using Fisher’s Exact Test where
applicable, with a Bonferroni adjustment. It is my un-
derstanding that this adjustment may be used when multiple
pairwise comparisons are made and that this makes it more
difﬁcult for any one comparison to be statistically signiﬁcant.
I question the appropriateness of this method when
evaluating a safety issue, when the more conservative
approach is desirable, and when only three pairwise
comparisons are involved. The rates of arthrocentesis in
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aol.com10the ﬁrst course of treatment in the repeat-course subgroup
(1 of 48 patients) and the second course of treatment in the
repeat-course subgroup (4 of 48 patients) (PZ 0.0194,
Fisher’s Exact) were indeed signiﬁcantly different without
this adjustment. Irrespective of the statistical analyses, the
incidence of patients requiring arthrocentesis following
treatment increased 4-fold upon repeat treatment, 2.1% vs
8.3%; in my view, this ﬁnding raises concern worthy of
discussion in the context of previous reports in the literature.
The authors’ comparisons to the results of Leopold et al.6
and Lussier et al.7 are difﬁcult to interpret and reconcile, as
it appears that the former reported on the incidence of
SAIRs, while the latter reported on the incidence of all local
adverse reactions of varying degrees of intensities. Neither
of these was a randomized study; they were both
retrospective and appeared to rely on spontaneous reports
from non-standardized methods of safety data capture used
by the individual practices. Accordingly, the true incidence
of SAIRs may have been underrepresented in these
reports. With that said, the 8.3% incidence of arthrocentesis
in the present study (if representative of the SAIRs’
frequency) is in line with a number of published reports.
At this point, the evidence associating hylan G-F 20 but
not sodium hyaluronates with SAIRs appears to be quite
solid: numerous published case reports and small clinical
studies have indicated that SAIRs are associated with hylan
G-F 20 injections (reviewed in Refs.2,3 with four primary
reports8e11 published since). None of these 16 published
reports to date are associated with the naturally extracted
avian products approved in the US that have been in global
use for 18 years, although a single report of a SAIRs-like
reaction to a fermented hyaluronan product (not approved
for use in the US) was recently published12. The preclinical
data are equally compelling for a hylan G-F 20-speciﬁc
reaction, and indicate that the mechanism for SAIRs is
immunologically based. We were the ﬁrst to report that
rabbits developed antibodies to chicken proteins when
injected with hylan G-F 20 but not with sodium hyaluronate.
Several reports in rabbits, guinea pigs and mice have all
conﬁrmed this original observation that hylan G-F 20 can
elicit antibody responses, passive cutaneous anaphylaxis,
inﬂammatory inﬁltrates after repeat exposure and granulo-
matous reactions, while two comparator naturally derived
sodium hyaluronate elicited no discernible reaction4,13e15.
Primates have also been shown to make antibody
responses to chicken proteins and/or hylan G-F 20 following
repeated intra-articular injections16. Most recently, we
identiﬁed a 6e8 kDa protein band that may be the
immunogenic target during SAIRs17. In clinical studies,
antibodies to hylan or chicken proteins have also been
noted in the sera of a patient undergoing a severe
pseudoseptic reaction18.
Although I applaud an investigation of product safety, it is
prudent to consider all available clinical and preclinical data
regarding hylan G-F 20 in conjunction with the safety39
1040 Letter to the Editorconclusions to allow readers to make informed decisions on
the appropriate therapeutic options for their OA patients.
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